title: [Evaluation of the role of rhIL-11 on hematological recovery in lymphoma patients after autologous hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To evaluate the effect of recombinant human interleukin 11 (rhIL-11) on hematological recovery after autologous hematopoietic stem cell transplantation (AHSCT) in patients with lymphoma.
  
  
  METHODS
  A retrospective study was carried out on 73 patients with lymphoma after AHSCT. The patients were divided into two groups. The study group (n = 35) received rhIL-11 1.5 mg daily from the fifth day after AHSCT to the day when platelets recovering to 80.0×10⁹/L. The control group (n = 38) did not receive rhIL-11 after AHSCT.
  
  
  RESULTS
  All the 73 patients finished AHSCT from Mar 2003 to Dec 2008 in our department. Thirty-five patients received rhIL-11 and 38 patients did not. In the rhIL-11 group and control group, the nadir of platelet was (18.9 ± 5.0)×10⁹/L and (21.5 ± 6.0)×10⁹/L, respectively, with a significant difference (P = 0.04). The median time of platelet recovering to 50.0×10⁹/L was (14.3 ± 5.5) d and (13.2 ± 4.5) d (P = 0.37) in the two groups. There was no significant difference (P = 0.82) in the median numbers of platelet transfusion in the two groups. The curves of the mean of daily absolute platelet counts of the two groups were similar (P = 0.22). Adverse events related to rhIL-11 were not found in the rhIL-11 group.
  
  
  CONCLUSIONS
  The results of this study do not show obviously accelerating effect of rhIL-11 on the platelet recovery in lymphoma patients after AHSCT and obvious increase of adverse events after rhIL-11 administration.
authors.affiliation: Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Jian-liang
authors.initials: JL
authors.lastname: Yang
authors.forename: Yuan-kai
authors.initials: YK
authors.lastname: Shi
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: He
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
authors.forename: Sheng-yu
authors.initials: SY
authors.lastname: Zhou
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Chang-gong
authors.initials: CG
authors.lastname: Zhang
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Han
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.forename: Lin
authors.initials: L
authors.lastname: Gui
authors.forename: Yan
authors.initials: Y
authors.lastname: Qin
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017370:Interleukin-11 / Q000008:administration & dosage*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D010976:Platelet Count; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D014182:Transplantation, Autologous
chemical_list: D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin